Erin Swailes
Primary Care · Hiawatha, IANPI 1932192390
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 28.9% of the total. Reporting peaked in 2023 at $1,137 and has fallen 67.3% since, to $371 in 2025. Among primary care clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$801
- Lilly USA, LLC$408
- Novo Nordisk$306
- Pfizer$212
- GSK$164
- plus $969 from 15 others
What the payments were for
- Food & beverage$4,019100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,161 |
| AstraZeneca | 31 | $801 |
| Lilly USA, LLC | 21 | $408 |
| Novo Nordisk | 17 | $306 |
| Pfizer | 12 | $212 |
| GSK | 3 | $164 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $160 |
| Exact Sciences | 10 | $159 |
| Amgen | 9 | $119 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| Boehringer Ingelheim | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Abbott | 3 | $60 |
| Merck | 4 | $59 |
| Mylan Specialty L.p. | 4 | $54 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Vertex | 1 | $18 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$126
How this compares
$4,019 in reported general payments places this provider in the 95th percentile of 36 primary care providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $60,974 |
| FarxigaDapagliflozin Propanediol | 45 | $58,421 |
| MounjaroTirzepatide | 43 | $47,077 |
| JanuviaSitagliptin Phosphate | 29 | $33,418 |
| EliquisApixaban | 24 | $27,515 |
| JardianceEmpagliflozin | 22 | $25,359 |
| XareltoRivaroxaban | 14 | $18,113 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $6,678 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,072 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,411 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,383 |
| Levothyroxine Sodium | 249 | $2,059 |
| Atorvastatin Calcium | 212 | $1,843 |
| Celecoxib | 23 | $1,773 |
| Metoprolol Succinate | 134 | $1,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $306 | $60,97464 claims |
| AstraZenecaFarxiga | $801 | $58,42145 claims |
| Lilly USA, LLCMounjaro | $408 | $47,07743 claims |
| MerckJanuvia | $59 | $33,41829 claims |
| PfizerEliquis | $212 | $27,51524 claims |
| Boehringer IngelheimJardiance | $65 | $25,35922 claims |
| Johnson & JohnsonXarelto | $31 | $18,11314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 primary care providers in Iowa.
Other primary care in Hiawatha
- Emily WickhamCouncil Bluffs$7K
- Jessica OgdenNewton$2K
- Jody HorstmanWest Des Moines$2K
- Chimene CobbLenox$2K
- Mary PedersenJefferson$1K
- Jamie HicksMilford$847
- Jennifer BlaylockAnkeny$787
- Catherine VailCouncil Bluffs$748
- Jennifer HutchinsonWest Union$664
- Roha AberaSioux City$607
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.